GlassScriptPhysician profile
Keith A Sacco
NPI 1780049759
$118,049.09
in general payments reported to CMS, 2019-2025
18 companies · $39K in 2025
The $39K reported for 2025 was more than what 95% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,037 · 2023: $78K · 2024: $263 · 2025: $39K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $87K · Honoraria: $11K · Travel and Lodging: $11K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,790 · Food and Beverage: $2,803.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $86,874.79 |
| Honoraria | $10,834.50 |
| Travel and Lodging | $10,709.39 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,790.00 |
| Food and Beverage | $2,803.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharming Healthcare, INC. | $87,569.44 | 2022-2025 | Joenja, Ruconest |
| Sumitomo Pharma America, INC. | $15,912.45 | 2023 | Rethymic |
| Horizon Therapeutics Plc | $13,050.72 | 2022-2023 | Actimmune |
| Csl Behring | $429.87 | 2022-2025 | Hizentra |
| Takeda Pharmaceuticals U.S.A., INC. | $359.47 | 2022-2023 | Cuvitru, Hyqvia |
| Genzyme Corporation | $146.26 | 2022-2023 | |
| Abbvie INC. | $124.99 | 2023 | Rinvoq |
| Adma Biomanufacturing LLC | $97.29 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.32 | 2022-2023 | |
| Amgen INC. | $55.52 | 2024 | Actimmune |
| Glaxosmithkline, LLC. | $47.46 | 2023 | Nucala, Benlysta |
| Regeneron Pharmaceuticals, INC. | $43.56 | 2022 | |
| Incyte Corporation | $39.23 | 2022-2023 | Opzelura |
| Pfizer INC. | $33.11 | 2022-2023 | |
| Phadia US INC. | $28.90 | 2023 | Immunocap |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $17.04 | 2022 | |
| Alk-Abello, INC | $13.96 | 2022 | |
| Novartis Pharmaceuticals Corporation | $13.50 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Sacco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.